Zenas BioPharma Stock Falls 20% After Pricing $300 Mln Offerings

Zenas BioPharma priced concurrent public offerings totaling $300M — $200M of convertible senior notes due 2032 and $100M of common stock — and shares fell about 20% on the news. The sizable debt and equity issuance signals dilution and funding pressure, driving the steep sell-off.

Analysis

Zenas BioPharma priced concurrent public offerings totaling $300M — $200M of convertible senior notes due 2032 and $100M of common stock — and shares fell about 20% on the news. The sizable debt and equity issuance signals dilution and funding pressure, driving the steep sell-off.